

Company Overview

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing innovative therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results

May 13 2019, 8:00 AM EDT

Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China

Apr 16 2019, 8:00 AM EDT

Rexahn Effects 1-for-12 Reverse Stock Split

Apr 12 2019, 8:00 AM EDT

Stock Overview

Symbol	RNN
Exchange	NYSE American
Market Cap	19.93m
Last Price	\$4.96
52-Week	\$4.71 - \$27.360001

05/24/2019 04:10 PM EDT

Investor Relations

ir@rexahn.com

Management Team

Douglas J. Swirsky

President and Chief Executive Officer

Lisa Nolan, Ph.D.

Chief Business Officer

DJ Kim, Ph.D.

Vice President and Head of Research and Development

Rexahn Pharmaceuticals, Inc.

15245 Shady Grove Road
Suite 455
Rockville, MD 20850

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.